MyMD Pharmaceuticals, Inc. (MYMD)

NASDAQ: MYMD · IEX Real-Time Price · USD
2.57
-0.04 (-1.35%)
Sep 27, 2022 3:38 PM EDT - Market closed
-1.35%
Market Cap 97.62M
Revenue (ttm) n/a
Net Income (ttm) -16.47M
Shares Out 38.06M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 177,860
Open 2.65
Previous Close 2.60
Day's Range 2.47 - 2.70
52-Week Range 1.88 - 9.95
Beta n/a
Analysts Buy
Price Target n/a
Earnings Date Nov 10, 2022

About MYMD

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a syn... [Read more...]

Industry Biotechnology
Founded 2014
CEO Howard Yeaton
Employees 9
Stock Exchange NASDAQ
Ticker Symbol MYMD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Buy
Stock Forecasts

News

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delay...

BALTIMORE, Md.--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of...

1 week ago - Business Wire

MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and ...

4 weeks ago - Business Wire

Data Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases...

1 month ago - Business Wire

MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Ext...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases...

2 months ago - Business Wire

MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to developing novel therapies for autoimmune and infla...

2 months ago - Business Wire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fidu...

NEW YORK , July 7, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim in...

2 months ago - PRNewsWire

MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Exten...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced further...

3 months ago - Business Wire

MyMD Pharmaceuticals' Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced positive...

5 months ago - Business Wire

MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Dela...

BALTIMORE, Md.--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced an ...

5 months ago - Business Wire

MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that Dr....

6 months ago - Business Wire

MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Ex...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that the...

7 months ago - Business Wire

MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending He...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced Phase 1 ...

7 months ago - Business Wire

MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announ...

8 months ago - Business Wire

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purch...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its...

Other symbols: ORMP
8 months ago - Business Wire

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches o...

NEW YORK, Dec. 16, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...

9 months ago - PRNewsWire

MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today ...

9 months ago - Business Wire

MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending L...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announ...

10 months ago - Business Wire

MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commerci...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its...

Other symbols: ORMP
10 months ago - Business Wire

MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announ...

10 months ago - Business Wire

MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chr...

11 months ago - Business Wire

MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it ...

11 months ago - Business Wire

MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over P...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data...

1 year ago - Business Wire

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healt...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it ...

1 year ago - Business Wire

MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C....

1 year ago - Business Wire

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma

BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on ...

1 year ago - Business Wire